InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,460.48
(
-0.41%
)
US TECH 100
19,181.60
(
-0.43%
)
Dow Jones
39,118.86
(
-0.12%
)
Brent Oil
84.85
(
0.00%
)
Bitcoin
61,680.36
(
1.30%
)
Post# of 77519
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

EZ2

Send PM Follow Ignore
Followers 213
Posts 219096
Boards Moderated 2
Alias Born 03/31/2001

EZ2

Re: The Rainmaker post# 35497

Wednesday, 09/07/2011 9:21:26 AM

Wednesday, September 07, 2011 9:21:26 AM

Post# of 77519

The Company is also in the process of forming a separate operating subsidiary to maximize the value of its intellectual property, specifically its biotech assets which the Company believes may have significant commercial value. These assets include its Anti-CD20 antibody which the Company believes to be a first cousin to Rituximab. Rituximab is scheduled to go off patent in 2015 and currently represents over 6.6 billion dollars in annual sales.

Gurus oversimplify everything. Investing, like life, is always more complicated than you think.

~ unknown

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up